Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase IIa Dose-Expansion and Biomarker Study of OPB-111077

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03158324
Recruitment Status : Recruiting
First Posted : May 18, 2017
Last Update Posted : June 15, 2017
Sponsor:
Collaborator:
Otsuka Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
National University Hospital, Singapore

Brief Summary:
This is a phase IIa open-label, non-randomized dose-expansion study of OPB-111077 in patients with advanced, treatment refractory cancers who have biopsy-amenable lesions at study entry.

Condition or disease Intervention/treatment Phase
NPC Refractory Tumor Drug: OPB-111077 Phase 2

Detailed Description:

This is a phase IIa open-label, non-randomized dose-expansion study of OPB-111077 in patients with advanced, treatment refractory cancers who have biopsy-amenable lesions at study entry. Patients on the proposed study will be treated with the RPII dose of OPB-111077 (600mg on a 4 days-on, 3 days-off per week schedule). They will be enrolled in two parallel cohorts: i. patients with tumors predicted to be dependent on oxidative phosphorylation metabolism or oncogene addicted tumors which have developed resistance to primary TKI therapy, or ii. patients with nasopharyngeal carcinoma

Each cohort will contain 11-26 patients, over a period of 12-36 months. Subjects will receive OPB-111077 in 28-day cycles till disease progression or intolerable toxicity. Mandatory tumour biopsies will be performed at baseline and on cycle 1 day 15 (where feasible and accessible). Circulating biomarker blood sampling will be performed on days 1, 11 and 15 of cycle 1, and upon completion of OPB-111077 dosing. Pharmacokinetics blood sampling will be performed on days 11 and 15 of cycle 1. Safety assessments will be performed on cycle 1 day 1, cycle 1 day 8, cycle 1 day 15, bi-weekly till week 8, then monthly thereafter and response assessments will be performed every 8 weeks. Metabolic response assessment by PET/CT will be performed after 2 cycles of treatment, while radiologic response assessment will be performed after every 2 cycles of OPB-111077 from cycle 4 onwards.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Two parallel cohorts will be implemented: i. patients with tumors predicted to be dependent on oxidative phosphorylation metabolism or oncogene addicted tumors which have developed resistance to primary TKI therapy, or ii. patients with nasopharyngeal carcinoma
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IIa Dose-Expansion and Biomarker Study of OPB-111077 in An Enriched Population of Treatment-Refractory Advanced Solid Tumors
Actual Study Start Date : May 22, 2017
Estimated Primary Completion Date : May 22, 2020
Estimated Study Completion Date : November 30, 2020

Arm Intervention/treatment
Experimental: Advanced refractory solid tumors
Patients with advanced refractory solid tumors will be enrolled.
Drug: OPB-111077
Receive 600 mg of OPB-111077 on a 4 days-on, 3 days-off per week in 28-day cycles till disease progression or intolerable toxicity




Primary Outcome Measures :
  1. Objective response rates [ Time Frame: 3 years ]
    This will be calculated as the percentage of evaluable patients achieving complete and partial response with OPB-111077 treatment, according to the RECIST 1.1 criteria


Secondary Outcome Measures :
  1. Metabolic response rates [ Time Frame: 3 years ]
    This will be calculated as the percentage of evaluable patients achieving complete and partial metabolic response on 18F]-FDG PET/CT after 2 cycles of OPB-111077, as determined by the EORTC PET response criteria.

  2. Progression free survival [ Time Frame: 3 years ]
    This is defined as the time from the start of study treatment to documented progression of disease or death.

  3. Haematologic and non-haematologic toxicities (all grades) [ Time Frame: 3 years ]
    To evaluate the haematologic and non-haematologic toxicities of OPB-111077



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed, locally recurrent or metastatic solid tumors, who have failed standard treatment
  2. Subjects with NPC will be eligible as long as they have received prior platinum therapy
  3. Subjects with other types of solid tumors will be eligible if: i) their archival tumor sample shows over-expression oxidative phosphorylation markers e.g., PGC-1α/ SIRT1 or ii) they have oncogene-addicted cancers (e.g., EGFR mutation-positive NSCLC, EML4-ALK fusion NSCLC, BRAF-mutant melanomas, GIST, RET-driven thyroid cancers) which have become resistant to primary TKI therapy
  4. All subjects must have at least one tumour lesion (primary or metastatic) that is suitable for free-hand or image-guided biopsy at baseline.
  5. Age ≥ 21 years, Eastern Cooperative Oncology Group (ECOG) performance status < 1
  6. Adequate bone marrow, liver and renal function
  7. Baseline serum lactate ¬<3mmol/l
  8. Capable of swallowing tablets
  9. Recovery from any previous drug- or procedure-related toxicity to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0 Grade 0 or 1 (except alopecia), or to baseline preceding the prior treatment.
  10. Signed informed consent obtained before any study specific procedure. Subjects must be able to understand and be willing to sign the written informed consent.

Exclusion Criteria:

  1. Chemotherapy, radiotherapy, surgery, immunotherapy or other therapy within 3 weeks of starting investigational medicinal product (IMP).
  2. Use of any prohibited medications (CYP3A4 inhibitors and inducers) or medications which may predispose to lactic acidosis (e.g., metformin, nucleoside analogue reverse within 1 week prior to start of study drug administration
  3. Pregnancy or breastfeeding.
  4. Women of childbearing potential not employing adequate contraception. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of study medication, and a negative result must be documented before start of study medication. Women of childbearing potential and men, must agree to use adequate contraception (barrier method of birth control) upon signing the informed consent form until at least 3 months after the last study drug administration.
  5. Known or suspected allergy to the investigational agent or any agent given in association with this study.
  6. Concurrent cancer which is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumours (Ta, Tis & T1) or any cancer curatively treated less than 3 years prior to study entry.
  7. Interstitial lung disease with ongoing signs and symptoms at the time of screening.
  8. Patients with CTCAE Grade 2 or higher peripheral neuropathy.
  9. History of significant cardiac disease: congestive cardiac failure > NYHA class II, ongoing unstable angina, new-onset angina or myocardial infarction within the past 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03158324


Contacts
Layout table for location contacts
Contact: Andrea Wong, MBBS (65) 6779 5555 andrea_la_wong@nuhs.edu.sg
Contact: Boon Cher Goh, MBBS (65) 6779 5555 phcgbc@nuhs.edu.sg

Locations
Layout table for location information
Singapore
National University Hospital, Singapore Recruiting
Singapore, Singapore, 119228
Contact: Andrea Wong, MBBS    +65 6772 4621    Andrea_LA_Wong@nuhs.edu.sg   
Sub-Investigator: Boon Cher Goh, MBBS         
Sponsors and Collaborators
National University Hospital, Singapore
Otsuka Pharmaceutical Co., Ltd.

Publications:
Layout table for additonal information
Responsible Party: National University Hospital, Singapore
ClinicalTrials.gov Identifier: NCT03158324    
Other Study ID Numbers: 2016/01181
First Posted: May 18, 2017    Key Record Dates
Last Update Posted: June 15, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No